natgillin/translations-raw huggingface dataset:
It induces an active and specific immunity against Bluetongue Virus in the vaccinated animal.
Ono inducira aktivnu i specifičnu imunost protiv virusa bolesti plavog jezika u cijepljenoj životinji.
Active substance*:
Djelatne tvari*:
Type I glass bottle of 10 ml with butyl elastomer closure.
Staklena bočica (tip I) od 10 ml sa čepom od butilnog elastomera.
BTVPUR suspension for injection for sheep and cattle
BTVPUR suspenzija za injekciju za ovce i goveda
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
6.6 Posebne mjere opreza za odlaganje neupotrebljenog veterinarsko-medicinskog proizvoda ili otpadnih materijala dobivenih primjenom tih proizvoda
For a monovalent vaccine containing an inactivated Bluetongue Virus serotypes 2 or 4, or for a bivalent vaccine containing both serotypes 2 and 4 together, one injection is sufficient.
Kod primjene monovalentne vakcine koja sadrži inaktivirani virus bolesti plavog jezika serotip 2 ili 4, ili kod bivalentne vakcine koja sadrži oba serotipa 2 i 4 zajedno, jedna injekcija je dovoljna.
PACKAGE LEAFLET: BTVPUR suspension for injection for sheep and cattle
UPUTA O VMP: BTVPUR suspenzija za injekciju za ovce i goveda
A confirmatory final potency test by seroneutralisation in rats is conducted when a batch is released
Konačni potvrdni test jačine, sero neutralizacija u štakora provodi se pri puštanju serije
INDICATION(S)
KARENCIJA(E)
Onset of immunity has been demonstrated 3 weeks (or 5 weeks in sheep for BTV2) after the primary vaccination course for BTV-1, BTV-2 (cattle), BTV-4 and BTV-8 serotypes.
Početak imunosti: 3 tjedna (ili 5 tjedana u ovce kod BTV2) nakon prvog cijepljenja sa serotipovima BTV-1, BTV-2 (govedo), BTV-4 i BTV-8.
A confirmatory final potency test by seroneutralisation in rats is conducted when a batch is released.
Konačni potvrdni test jačine, sero neutralizacija u štakora provodi se pri puštanju serije.
Avoid multiple vial broaching.
Izbjegavajte višekratno otvaranje bočica.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Stoga odluka o primjeni ovog cjepiva prije, odnosno poslije primjene bilo kojeg drugog veterinarsko-medicinskog proizvoda treba donositi od slučaja do slučaja.
Shelf life of monovalent or bivalent formulation with Bluetongue Virus serotypes 2 (100 ml, 50 ml and 10 ml bottles) and/or 4 (10 ml bottles): 18 months.
Rok valjanosti monovalentne ili bivalentne formulacije s virusom bolesti plavog jezika serotip 2 (100 ml, 50 ml i 10 ml bočica) i/ ili 4 (10 ml bočica): 18 mjeseci.
Withdrawal period: zero days
Karencija: nula dana
Shelf life of monovalent or bivalent formulation with Bluetongue Virus serotypes 1, 8 (100 ml, 50 ml and 10 ml bottles) and/or 4 (100 ml and 50 ml bottles): 2 years.
Rok valjanosti monovalentne ili bivalentne formulacije s virusom bolesti plavog jezika serotip 1, 8 (100 ml, 50 ml i 10 ml bočica) i/ ili 4 (100 ml i 50 ml bočica): 2 godine.
• Revaccination Annual.
• Docjepljivanje: Jednom godišnje.
B. CONDITIONS OR RESTRICTIONS OF REGARDING SUPPLY OR USE
UVJETI ILI OGRANIČENJA U POGLEDU OPSKRBE I PRIMJENE
Manufacturer responsible for batch release: MERIAL
Nositelj odobrenja za proizvodnju odgovoran za puštanje serije u promet: MERIAL
Subcutaneous use.
Potkožna primjena.
Inactivated BTV1 ..................................................................................................... ≥ 1.9 log10 pixels Inactivated BTV2 ................................................................................................... ≥ 1.82 log10 pixels Inactivated BTV4 ................................................................................................... ≥ 1.86 log10 pixels Inactivated BTV8 ................................................................................................... ≥ 2.12 log10 pixels (*) maximum of two different inactivated bluetongue virus serotypes.
Inaktivirani BTV1 .................................................................................................. ≥ 1.9 log10 piksela Inaktivirani BTV2 ................................................................................................ ≥ 1,82 log10 piksela Inaktivirani BTV4 ................................................................................................ ≥ 1.86 log10 piksela Inaktivirani BTV8 ................................................................................................ ≥ 2.12 log10 piksela (*) maksimum dva različita serotipa inaktiviranog virusa bolesti plavog jezika
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
PROIZVOĐAČ BIOLOŠKI DJELATNE TVARI I PROIZVOĐAČ ODGOVORAN
Bottle of 10 and 50 ml
Bočica od 10 ml i 50 ml
Disposal: read package leaflet
Zbrinjavanje: pročitati uputu.
Box of 1 bottle of 10 doses (1 x 10 ml)
Kutija s 1 bočicom od 10 doza (1 x 10 ml).
Bottle of 100 ml
Bočica od 100 ml
6.4 Special precautions for storage
6.4 Posebne mjere opreza pri čuvanju
10 doses (10 ml) 50 doses (50 ml)
50 doza (50 ml).
Very rare and transient apathy can be observed after the administration of a double-dose of the vaccine.
Nakon primjene dvostruke doze cjepiva vrlo rijetko je primijećena prolazna apatija.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
4.10 Predoziranje (simptomi, hitni postupci, antidoti), ako je nužno Nakon primjene dvostruke doze cjepiva vrlo rijetko je primijećena prolazna apatija.
In very rare cases it has been observed a small local swelling at the injection site (at most 32 cm² in cattle and 24 cm² in sheep) which becomes residual 35 days later (≤ 1 cm In very rare cases a transient increase in body temperature, normally not exceeding an average of 1.1 ºC, may occur within 24 hours after vaccination.
U vrlo rijetkim slučajevima može se pojaviti prolazno povišenje tjelesne temperature, obično ne prelazi više od 1,1 °C, 24 sata nakon cijepljenja.
Special precautions for use in animals: Not applicable.
Posebna upozorenja za upotrebu kod životinja:
Box of 10 bottles of 100 ml
Kutija s 10 bočica od 100 ml
Laboratory of Lyon Porte des Alpes Rue de l'Aviation,
Laboratory od Lyon Porte des Alpes
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
- rijetke (više od 1 ali manje od 10 životinja na tretiranih 10.000 životinja).
Active immunisation of cattle to prevent viraemia* caused by bluetongue virus serotypes 1, 2, 4 and/or 8, and to reduce clinical signs caused by bluetongue virus serotypes 1, 4 and/or 8 (combination of maximum 2 serotypes).
Aktivna imunizacija goveda za sprečavanje viremije* uzrokovane virusom bolesti plavog jezika serotipova 1, 2, 4 i/ili 8 te smanjenje kliničkih znakova uzrokovanih virusom bolesti plavog jezika serotipova 1, 4 i/ili 8 (kombinacija najviše dva različita soja).
Inactivated bluetongue virus ........................................ strain specific pass level (log10 pixels) ** (*) maximum of two different inactivated bluetongue virus serotypes
Inaktivirani virus bolesti plavog jezika ………………≥ nivo specifičnog soja (log10 piksela)** (*) maksimum dva različita serotipa inaktiviranog virusa
Adjuvants: Al
Al
Inactivated Bluetongue Virus ......................................... strain specific pass level (log10 pixels) ** * maximum of two different inactivated bluetongue virus serotypes
Inaktivirani virus bolesti plavog jezika ………………≥ nivo specifičnog soja (log10 piksela)** * maksimum dva različita serotipa inaktiviranog virusa bolesti plavog jezika
Active immunisation of sheep to prevent viraemia* and to reduce clinical signs caused by Bluetongue Virus Serotypes 1, 2, 4 and/or 8 (combination of maximum 2 serotypes).
Aktivna imunizacija ovaca za sprečavanje viremije* i smanjenje kliničkih znakova uzrokovanih virusom bolesti plavog jezika serotipovi 1, 2, 4 i/ili 8 (kombinacija najviše dva različita soja).
Active immunisation of sheep to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotypes 1, 2, 4 and/or 8 (combination of maximum 2 serotypes).
Aktivna imunizacija ovaca za sprečavanje viremije* i smanjenje kliničkih znakova uzrokovanih virusom bolesti plavog jezika serotipova 1, 2, 4 i/ili 8 (kombinacija najviše dva različita soja).
Box of 1 bottle of 50 ml,
Kutija s 1 bočicom od 50 ml
1.82 log10 pixels/mL
1,82 log10 piksela/mL
1.86 log10 pixels/mL
1,86 log10 piksela/mL
Box of 10 bottles of 50 ml,
Kutija s 10 bočica od 50 ml
2.12 log10 pixels/mL
2,12 log10 piksela/mL
• Primary vaccination
• Prvo cijepljenje
Box of 1 bottle of 100 ml,
Kutija s 1 bočicom od 100 ml
1.9 log10 pixels/mL
1,9 log10 piksela/mL
In cattle: - First injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune cattle).
U goveda - Prva injekcija: od 1 mjeseca starosti u prethodno necijepljenih životinja (ili od 2,5 mjeseca starosti u mladih životinja oteljenih od imunih krava).
In sheep: - First injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune sheep).
U ovaca - Prva injekcija: od 1 mjeseca starosti u prethodno necijepljenih životinja (ili od 2,5 mjeseca starosti u mladih životinja ojanjenih od imunih ovca).
In very rare cases it has been observed a small local swelling at the injection site (at most 32 cm² in cattle and 24 cm in sheep) which becomes residual 35 days later (≤ 1 cm In very rare cases a transient increase in body temperature, normally not exceeding an average of 1.1ºC, may occur within 24 hours after vaccination.
24 cm u ovaca) na mjestu uboda, koji se povlači za 35 dana (≤ 1 cm 2) nakon cijepljenja.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
OSNOVNI PODACI NA UNUTARNJEM PAKOVANJU
None
I
Al3+ (as hydroxide) .................................................................................................................. 2.7 mg Saponin ................................................................................................................................... 30 HU** (**)Haemolytic units
(kao hidroksid) ................................................................................................................... 2,7 mg Saponin ................................................................................................................................... 30 HU** Hemolitičke jedinice
In cattle st injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune cattle).
U goveda: - Prva injekcija: od 1 mjeseca starosti u prethodno necijepljenih životinja (ili od 2,5 mjeseca starosti u mladih životinja oteljenih od imunih krava).
MA (EU) Number
EU broj odobrenja
(Invented) name
(Zaštićeni) naziv lijeka
Route of Administration
Način primjene
Invented name Strength Pharmaceutical Form Route of Administration
Broj EU odobrenja Zaštićeno ime Doza
The valid summary of product characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure.
Važeći sažetak opisa svojstava lijeka, označavanje i uputa o lijeku konačne su verzije dovršene tijekom postupka koordinacijske skupine.
The overall response rate was 14.1 %.
Stopa ukupnog odgovora iznosila je 14,1%.
You might have any of these symptoms and/or conditions.
Možete dobiti bilo koji od navedenih simptoma i/ili stanja.
Additional medicines:
Dodatni lijekovi:
Thirst and increased water consumption
Žeđ i povećan unos vode
Date of latest renewal: 20 September 2009
Datum posljednje obnove odobrenja: 20. rujna 2009.
* Definition of frequency terms: Very common - ≥ 10%; Common - > 5% and < 10%.
* Definicije pojmova učestalosti: vrlo često - ≥ 10%; često - > 5% i < 10%.
What ALIMTA is and what it is used for
Što je ALIMTA i za što se koristi
Instructions for use, handling and disposal.
Upute za uporabu, rukovanje i odlaganje.
Infection (sepsis) may be severe and could lead to death.
Infekcija (sepsa) može biti vrlo teška i potencijalno smrtonosna.
Any diarrhoea requiring hospitalisation (irrespective of grade) or grade 3 or 4 diarrhoea.
Svaki proljev koji zahtijeva hospitalizaciju (bez obzira na stupanj) ili proljev stupnja 3 ili 4
If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor.
Ako ste trudni, mislite da biste mogli biti trudni ili planirate imati dijete, obavijestite o tome svog liječnika.
Anaphylactic shock (severe allergic reaction)
Anafilaktički šok (teška alergijska reakcija)
Other medicines and ALIMTA
Drugi lijekovi i ALIMTA
The pH of the reconstituted solution is between 6.6 and 7.8.
pripremljene otopine je između 6,6 i 7,8.
Animal studies have shown reproductive toxicity (see section 5.3).
Istraživanja na životinjama pokazala su reproduktivnu toksičnost (vidjeti dio 5.3).
Based on the planned date of your infusion of ALIMTA and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them.
Ovisno o planiranom datumu primjene infuzije lijeka ALIMTA i/ili Vašoj bubrežnoj funkciji, liječnik Vam mora reći koje lijekove možete uzimati i kada ih možete uzimati.
ALIMTA is a medicine used in the treatment of cancer.
ALIMTA je lijek koji se koristi za liječenje raka.
Pharmacotherapeutic group: Folic acid analogues, ATC code: L01BA04
Farmakoterapijska skupina: analozi folatne kiseline, ATK oznaka: L01BA04
Talk to your doctor or hospital pharmacist before receiving ALIMTA.
Obratite se svom liječniku ili bolničkom ljekarniku prije nego primite lijek ALIMTA.
Your doctor will discuss with you the potential risk of taking ALIMTA during pregnancy.
Liječnik će s Vama razgovarati o mogućem riziku primjene lijeka ALIMTA u trudnoći.
What you need to know before you use ALIMTA
Što morate znati prije nego počnete primati lijek ALIMTA
Caution should be made when these drugs are combined with pemetrexed.
Potreban je oprez kada se ti lijekovi kombiniraju s pemetreksedom.
You must tell your doctor as soon as possible when you start experiencing any of these side effects.
Morate što prije obavijestiti svog liječnika ako primijetite bilo koju od ovih nuspojava.
From a microbiological point of view, the product should be used immediately.
S mikrobiološkog stajališta lijek se mora odmah primijeniti.
In vitro studies indicate that pemetrexed is approximately 81 % bound to plasma proteins.
Ispitivanja in vitro pokazuju da se oko 81% pemetrekseda veže za proteine u plazmi.
Between patient variability in clearance is moderate at 19.3 %.
Varijabilnost klirensa između pojedinih bolesnika je umjerena i iznosi 19,3%.
CTC a Grade
CTC a stupanj
Cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of ALIMTA has finished.
Cisplatin se također primjenjuje infuzijom u jednu od vena i daje se približno 30 minuta nakon završetka infuzije lijeka ALIMTA.
Event**
Događaj**
2 rue du Colonel Lilly 67640 Fegersheim France
2 rue du Colonel Lilly 67640 Fegersheim Francuska
Efficacy and safety were measured from the time of randomisation after completion of first line (induction) therapy.
Djelotvornost i sigurnost mjereni su od randomizacije nakon završetka prve linije liječenja (uvodnog liječenja).
a Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p <0.001).
a Statistički značajan za neinferiornost, a cijeli interval pouzdanosti za HR nalazi se znatno ispod granice neinferiornosti od 1,17645 (p < 0,001).
Taking into account the PRAC Assessment Report on the PSUR(s) for pemetrexed, the scientific conclusions of the CHMP are as follows:
Uzimajući u obzir PRAC-ovo izvješće o ocjeni periodičkog(ih) izvješća o neškodljivosti lijeka (PSUR) za pemetreksed, znanstveni zaključci CHMP-a su sljedeći:
In Vitro studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter.
Ispitivanja in vitro pokazuju da se pemetreksed aktivno izlučuje putem OAT3 (organskog anionskog transportera).
When using ALIMTA in combination with cisplatin:
Kad se ALIMTA primjenjuje u kombinaciji s cisplatinom:
Pemetrexed should not be used during pregnancy unless clearly necessary, after a careful consideration of the needs of the mother and the risk for the foetus (see section 4.4).
Pemetreksed se ne smije primjenjivati u trudnoći, osim ako je to doista nužno i tek nakon što se pažljivo razmotre potrebe majke i mogući rizik za plod (vidjeti dio 4.4).
If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs.
Ako niste sigurni, pitajte svog liječnika ili ljekarnika je li koji od Vaših lijekova
Response (n: qualified for response) Response rate (%) (95 % CI) Stable disease (%)
Odgovor (n: broj bolesnika u kojih se mogao ocijeniti odgovor) stopa odgovora (%) (95% CI) stabilna bolest (%)
Taste change
Promjena okusa
Pre-treatment with dexamethasone (or equivalent) can reduce the incidence and severity of skin reactions (see section 4.2).
Prethodnim davanjem deksametazona (ili ekvivalentnog lijeka) mogu se smanjiti incidencija i težina kožnih reakcija (vidjeti dio 4.2).
Particular attention should be paid to these patients and caution exercised with use of other radiosensitising agents.
Treba obratiti posebnu pozornost na te bolesnike i uz oprez primjenjivati druge lijekove koji povećavaju osjetljivost na zračenje.
The total bilirubin should be ≤ 1.5 times upper limit of normal.
Vrijednost ukupnog bilirubina mora biti ≤ 1,5 puta iznad gornje granice normalnih vrijednosti.
There are no data from the use of pemetrexed in pregnant women but pemetrexed, like other anti-metabolites, is suspected to cause serious birth defects when administered during pregnancy.
Nema podataka o primjeni pemetrekseda u trudnica, no sumnja se da pemetreksed, kao i ostali antimetaboliti, uzrokuje teške prirođene mane ako se primjenjuje tijekom trudnoće.
You will always receive ALIMTA by infusion into one of your veins.
Lijek ALIMTA uvijek ćete primiti infuzijom u jednu od vena.
The European Medicines Agency has waived the obligation to submit the results of studies with ALIMTA in all subsets of the paediatric population in the granted indications (see Section 4.2).
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka ALIMTA u svim podskupinama pedijatrijske populacije za odobrene indikacije (vidjeti dio 4.2).
You will also receive an injection of vitamin B12 (1000 micrograms) in the week before administration of ALIMTA and then approximately every 9 weeks (corresponding to 3 courses of ALIMTA treatment).
Također ćete dobiti injekciju vitamina B12 (1000 mikrograma) u tjednu prije primjene lijeka ALIMTA i zatim otprilike svakih 9 tjedana (što odgovara 3 ciklusa liječenja lijekom ALIMTA).
You must contact your doctor immediately if you notice any of the following: Fever or infection (common): if you have a temperature of 38ºC or greater, sweating or other signs of infection(since you might have less white blood cells than normal which is very common).
Morate se odmah javiti svom liječniku ako primijetite bilo što od sljedećeg: vrućicu ili infekciju (često): ako Vam je tjelesna temperatura 38°C ili viša, ako se znojite ili imate neke druge znakove infekcije (jer broj bijelih krvnih stanica može biti niži od normalnog,
Alkaline phosphatase (AP), aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) should be ≤ 3 times upper limit of normal.
Vrijednosti alkalne fosfataze (ALP), aspartat aminotransferaze (AST ili SGOT) i alanin aminotransferaze (ALT ili SGPT) moraju biti ≤ 3 puta iznad gornje granice normalnih vrijednosti.
What ALIMTA contains
Što ALIMTA sadrži
Efficacy of ALIMTA vs docetaxel in NSCLC - ITT population ALIMTA
Djelotvornost lijeka ALIMTA u odnosu na docetaksel kod NSCLC - ITT populacija ALIMTA
Log Rank p-value*
Log-rang p-vrijednost*
Common Pain Edema Renal Disorders Common Renal disorders**** Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacectic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase.
Kratice: ALT = alanin aminotransferaza; AST = aspartat aminotransferaza; CTCAE = Zajednička terminologija za nuspojave; NCI = Nacionalni institut za rak; SGOT = serumska glutamat-oksaloctena aminotransferaza; SGPT = serumska glutamat piruvična aminotransferaza.
Kaplan Meier plots of overall survival by histology
Kaplan Meierove krivulje ukupnog preživljenja prema histološkom tipu tumora
If you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive ALIMTA.
Ako trenutno imate ili ste prethodno imali problema s bubrezima, obratite se svom liječniku ili bolničkom ljekarniku jer možda nećete smjeti primati lijek ALIMTA.
You must take at least 5 doses during the seven days before the first dose of ALIMTA.
Morate uzeti barem 5 doza tijekom 7 dana prije prve doze lijeka ALIMTA.
Pemetrexed N = 265
Pemetreksed N = 265
Alimta can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy.
ALIMTA Vam se može propisati ako imate rak pluća u uznapredovaloj fazi i ako je Vaša bolest reagirala na liječenje ili ostala uglavnom nepromijenjena nakon početne kemoterapije.
Fisher's exact p-value*
Fisherova egzaktna p-vrijednost
Therefore, patients should receive adequate antiemetic treatment and appropriate hydration prior to and/or after receiving treatment.
Iz tog razloga bolesnici moraju primiti odgovarajući antiemetik i prikladnu hidrataciju prije i/ili nakon primjene terapije.
75 % of previous dose (both ALIMTA and cisplatin)
75% prethodne doze (i lijeka ALIMTA i cisplatina)
Prior chemotherapy did not include ALIMTA.
Prethodna kemoterapija nije uključivala lijek ALIMTA.
Dose of ALIMTA (mg/m2)
Doza lijeka ALIMTA (mg/m2)
On the basis of the scientific conclusions for pemetrexed the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing pemetrexed is unchanged subject to the proposed changes to the product information
Na temelju znanstvenih zaključaka za pemetreksed, CHMP smatra da je omjer koristi i rizika lijeka(ova) koji sadrži(e) pemetreksed nepromijenjen, uz predložene izmjene informacija o lijeku.
The independent review of patient scans confirmed the findings of the investigator assessment of PFS.
Neovisna procjena snimaka bolesnika potvrdila je zaključke ispitivača pri procjeni PFS
As a result, concomitant use of live attenuated vaccines is not recommended (see section 4.3 and 4.5).
Stoga se ne preporučuje istodobna primjena živih atenuiranih cjepiva (vidjeti dijelove 4.3 i 4.5).
First line doublet therapy containing ALIMTA was not included.
Nije bila uključena prva linija dvojne terapije koja je sadržavala lijek ALIMTA.
Concomitant use not recommended: Live attenuated vaccines (except yellow fever, for which concomitant use is contraindicated): risk of systemic, possibly fatal, disease.
Ne preporučuje se istodobna primjena živih atenuiranih cjepiva (osim cjepiva protiv žute groznice, čija je istodobna primjena kontraindicirana), zbog rizika od sustavne bolesti koja može biti smrtonosna.
Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive ALIMTA.
Prije svake infuzije uzet će Vam se uzorak krvi kako bi se provjerilo jesu li Vam bubrežna ili jetrena funkcija dovoljno dobre i imate li dovoljno krvnih stanica da biste primili lijek ALIMTA.